


Ask a doctor about a prescription for CITALOPRAM TARBIS 20 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Citalopram TARBIS 20 mg Film-Coated Tablets EFG
Citalopram (hydrobromide)
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Citalopram is an antidepressant medication that belongs to the group of medications called "selective serotonin reuptake inhibitors".
Citalopram TARBIS is indicated for:
Also, consult the section "Taking Citalopram TARBIS with other medications" below.
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Citalopram TARBIS.
It has been observed that there is an increased risk of bone fractures in patients treated with this type of medication.
Suicidal Thoughts and Worsening of Depression or Anxiety Disorder
If you are depressed and/or suffer from an anxiety disorder, you may sometimes have thoughts of self-harm or suicide. These can increase when taking antidepressants for the first time, as all these medications require time to start taking effect, usually around two weeks, although in some cases it may take longer.
You are more likely to have these thoughts:
If at any time you have thoughts of self-harm or suicide, contact your doctor or go directly to a hospital.
It may be helpful for you to tell a relative or close friend that you are depressed or have an anxiety disorder and ask them to read this package leaflet. You can ask them if they think your depression or anxiety disorder has worsened, or if they are concerned about changes in your behavior.
When treatment is discontinued, it is common for withdrawal symptoms to appear, particularly if the treatment is discontinued abruptly (see section "Possible Side Effects").
Use in Children and Adolescents Under 18 Years
Citalopram TARBIS should not normally be used in the treatment of children and adolescents under 18 years. At the same time, you should know that in patients under 18 years, there is a higher risk of adverse effects such as suicidal attempts, suicidal ideas, and hostility (mainly aggression, confrontational behavior, and irritation) when taking this class of medications. Nevertheless, the doctor may prescribe Citalopram TARBIS 20 mg to patients under 18 years when they decide it is most convenient for the patient. If the doctor has prescribed Citalopram TARBIS 20 mg to a patient under 18 years and you want to discuss this decision, please go back to your doctor. You should inform your doctor if any of the symptoms mentioned above progress or if you experience complications when patients under 18 years are taking Citalopram TARBIS 20 mg. Also, the long-term effects on safety and related to growth, maturity, and cognitive and behavioral development of Citalopram TARBIS 20 mg in this age group have not yet been demonstrated.
Taking Citalopram TARBIS with Other Medications
Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
Do not take Citalopram TARBIS:
If you are taking medications because you already have a disease that affects heart rhythm or if you are taking medications that may affect heart rhythm, such as antiarrhythmics class IA and III, antipsychotics (e.g., phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antimicrobials (sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, antimalarial medications, particularly halofantrine), certain antihistamines (astemizole, mizolastine).
If you have doubts about this, consult your doctor.
The simultaneous administration of citalopram with non-selective or selective B monoamine oxidase inhibitors (MAOIs) (such as selegiline, an antiparkinsonian medication) and during the two weeks following the end of treatment is contraindicated.
The simultaneous administration of citalopram with selective A monoamine oxidase inhibitors (MAOIs) (such as moclobemide, an antidepressant medication) is not recommended.
The simultaneous administration of citalopram with MAOIs carries a risk of serotonin syndrome (see "Possible Side Effects" section).
Precautions should be taken if citalopram is administered with any of the following medications:
Taking Citalopram TARBIS with Food, Drinks, and Alcohol
It is advisable to avoid consuming alcohol while taking this medication.
Pregnancy, Breastfeeding, and Fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
The use of citalopram is not recommended during pregnancy and breastfeeding.
If you take Citalopram TARBIS in the final stage of pregnancy, there may be a higher risk of abundant vaginal bleeding shortly after delivery, especially if you have a history of bleeding disorders. Your doctor or midwife should know that you are taking Citalopram TARBIS to advise you.
Make sure your midwife and/or doctor knows that you are taking Citalopram TARBIS. When taken during pregnancy, particularly in the last 3 months of pregnancy, medications like Citalopram TARBIS may increase the risk of a serious disease in newborns called persistent pulmonary hypertension of the newborn (PPHN), which makes the baby breathe faster and turn blue. These symptoms usually start within the first 24 hours after the baby is born. If this happens to your baby, contact your midwife and/or doctor immediately.
Animal studies have shown that citalopram reduces sperm quality. Theoretically, this could affect fertility, but the impact on human fertility has not been observed yet.
Driving and Using Machines
During treatment with Citalopram TARBIS, you may feel drowsy or dizzy. Do not drive or operate tools or machines until you know how the treatment with Citalopram TARBIS 20 mg affects you.
Citalopram TARBIS contains Lactose
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow the administration instructions of this medication exactly as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Remember to take your medication.
Your doctor will indicate the duration of your treatment with Citalopram TARBIS. Do not discontinue treatment before or abruptly, as it may worsen your condition.
You should continue taking your medication even if you do not notice improvement, as it may take several weeks for the medication to start working.
Citalopram TARBIS are tablets for oral administration. The tablets can be taken at any time of the day, regardless of meals, and in a single dose. They should be swallowed with a sufficient amount of liquid (a glass of water) and without chewing.
The recommended dose is:
Adults:
Depression
The usual dose is 20 mg per day. If necessary, your doctor may increase this dose up to a maximum of 40 mg per day.
Anxiety Disorder
The initial dose is 10 mg per day for the first week before increasing it to 20-30 mg per day. If necessary, your doctor may increase this dose up to a maximum of 40 mg per day.
Obsessive-Compulsive Disorder (OCD)
The usual dose is 20 mg per day. If necessary, your doctor may increase this dose up to a maximum of 40 mg per day.
In elderly patients, treatment should be started with half the recommended dose, for example, 10-20 mg per day.
In general, elderly patients should not take more than 20 mg per day.
Patients with Special Risks
Patients with liver disease should not take more than 20 mg per day.
Patients with Renal Insufficiency:
The use of citalopram is not recommended in patients with severe renal insufficiency.
The safety and efficacy of Citalopram TARBIS 20 mg have not been established in children and adolescents under 18 years, so its use is not recommended in this population.
If you think the effect of Citalopram TARBIS 20 mg is too strong or too weak, tell your doctor or pharmacist.
If you take more Citalopram TARBIS than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
The most frequent symptoms in case of overdose are: nausea, vomiting, sweating, drowsiness, blue discoloration of the skin, tremors, seizures, loss of consciousness, and palpitations.
If you forget to take Citalopram TARBIS
In case of forgetting a dose, wait for the next one.
Do not take a double dose to make up for the missed doses.
If you interrupt treatment with Citalopram TARBIS
If treatment with Citalopram TARBIS 20 mg is discontinued abruptly, some disorders due to withdrawal may occur, such as dizziness, nausea, sweating, sensory disturbances, sleep disturbances, headache, agitation, or anxiety, and a sensation of tingling in the hands or feet. The risk of withdrawal reactions depends on several factors, including the duration of treatment, the dose used, and the rate of dose reduction. Generally, these symptoms are mild or moderate, but in some patients, they can be severe. Usually, these symptoms are self-limiting and resolve within two weeks, although in some patients, their duration may be prolonged. Your doctor will advise you on how to gradually discontinue treatment with this medication.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Side effects are generally mild or moderate. They will be evident during the first and even the first two weeks of treatment and will then disappear as the disease improves.
The following side effects have been reported. If you notice any of the following symptoms, stop taking Citalopram TARBIS and consult your doctor immediately:
Rarely, cases of bleeding in the skin and mucous membranes, such as skin hemorrhages, vaginal bleeding, and gastrointestinal bleeding, have been observed.
Reporting of Side Effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that is not listed in this package leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications, Website: www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medicine out of the sight and reach of children.
No special storage conditions are required.
Expiry Date
Do not use this medicine after the expiry date stated on the packaging after CAD. The expiry date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medicines at the pharmacy's SIGRE Point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition of Citalopram TARBIS 20 mg Tablets
Appearance of the Product and Package Contents
Citalopram TARBIS 20 mg are film-coated tablets, white, oval, biconvex, and scored. They are available in packs of 14, 28, 56, and 500 (clinical pack) tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
TARBIS FARMA, S.L.
Gran vía Carlos III, 94
08028 – Barcelona
Spain
Manufacturer
Toll Manufacturing Services, S.L.
C/Aragoneses, 2
28108 Alcobendas (Madrid)
Spain
Date of Last Revision of this Leaflet: December 2020
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of CITALOPRAM TARBIS 20 mg FILM-COATED TABLETS in November, 2025 is around 5.12 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for CITALOPRAM TARBIS 20 mg FILM-COATED TABLETS – subject to medical assessment and local rules.